UNSPSC 51172015: Florantyrone

This classification denotes a cholagogue or choleretic agent with the molecular formula C20H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UZ5LMI200P, chemically known as 8-fluoranthenebutyric acid, gamma-oxo- but generally known as florantyrone, which bears US NIH Compound Identifier 10617. European Medicines Agency schedules Florantyrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07648MIG.

UNSPSC 51172015 Florantyrone, a Commodity code, encompasses pharmaceutical products and testing materials that state and local governments procure for correctional, health, and welfare programs. Recent solicitations show state and local buyers purchasing drug-testing supplies and services, generic pharmaceuticals for distribution networks, and direct-to-manufacturer prescription fulfillment capabilities. Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services, seeking vendors to staff collection sites, operate randomized testing notification systems, and perform immunoassay screening with LC/MS/MS or GC/MS confirmation across approximately 25,031 annual tests on a per-test pricing basis. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with evaluation weighted 75 percent on price competitiveness and 25 percent on administrative compliance and operational capability.

Activity under this code spans state health and human services departments, county correctional and community supervision agencies, and multistate cooperative purchasing alliances. Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 seeking vendor information on direct-to-manufacturer prescription programs for self-insured employee group health plans and state agencies. Geographic concentration is evident in Texas and Minnesota, with Collin County (Texas) pursuing a $600,000 two-year offender testing contract commencing September 1, 2026 with three optional one-year renewals, and MMCAP offering two-year generic pharmaceutical agreements effective July 1, 2026 with optional extensions through June 30, 2028. Pricing models vary: Collin County requires per-test rates with no additional surcharges and price redetermination limited to September 1 anniversaries based on medical Consumer Price Index increases not exceeding 3.0 percent, while MMCAP evaluates fixed pricing, net price formats, and WAC-minus structures with a mandatory 3 percent administrative fee on all purchases.